Circulating immune checkpoints predict heart failure outcomes

Circulating immune checkpoints predict heart failure outcomes

Abstract Aims There are limited data examining the role of immune checkpoint (IC) ligands in the pathophysiology of heart failure (HF). Therefore, we explore this in three HF animal models and in three different human cohorts (healthy, stable, and worsening HF). Methods and results Transcriptomic an...

Cur síos iomlán

Sonraí bibleagrafaíochta
Príomhchruthaitheoirí:	Elles M. Screever, Laura I.E. Yousif, Javid J. Moslehi, Joe‐Elie Salem, Adriaan A. Voors, Herman H.W. Silljé, Rudolf A. deBoer, Wouter C. Meijers
Formáid:	Alt
Teanga:	English
Foilsithe / Cruthaithe:	Wiley 2023-08-01
Sraith:	ESC Heart Failure
Ábhair:	Immune checkpoints PD‐L1 PD‐L2 Galectin‐9 Heart failure
Rochtain ar líne:	https://doi.org/10.1002/ehf2.14304

Míreanna comhchosúla

Neurologic toxicity associated with immune checkpoint inhibitors: a pharmacovigilance study
de réir: Douglas B. Johnson, et al.
Foilsithe / Cruthaithe: (2019-05-01)

Checkpoint Inhibition in Myeloma: Opportunities and Challenges
de réir: Federica Costa, et al.
Foilsithe / Cruthaithe: (2018-09-01)

The role of immune checkpoints in cardiovascular disease
de réir: Laura I. Yousif, et al.
Foilsithe / Cruthaithe: (2022-10-01)

Enhancing cancer care with improved checkpoint inhibitors
de réir: Vickram A S, et al.
Foilsithe / Cruthaithe: (2024-10-01)

Checkmate with checkpoint inhibitors: New paradigm in immunotherapy
de réir: Ruby Dhar, et al.
Foilsithe / Cruthaithe: (2023-04-01)

Characterization of PD-1/PD-L1 Immune Checkpoint Expression in Osteosarcoma
de réir: Kazuhiko Hashimoto, et al.
Foilsithe / Cruthaithe: (2020-07-01)

Immune Checkpoint in Glioblastoma: Promising and Challenging
de réir: Jing Huang, et al.
Foilsithe / Cruthaithe: (2017-05-01)

Phytochemicals in Cancer Immune Checkpoint Inhibitor Therapy
de réir: Juwon Lee, et al.
Foilsithe / Cruthaithe: (2021-07-01)

Overview of the Cardiotoxicity Induced by PD-1/PD-L1 Immune Checkpoint Inhibitor in Critical Care
de réir: Ruiting Li, et al.
Foilsithe / Cruthaithe: (2021-06-01)

On Demand Biosensors for Early Diagnosis of Cancer and Immune Checkpoints Blockade Therapy Monitoring from Liquid Biopsy
de réir: Sai Mummareddy, et al.
Foilsithe / Cruthaithe: (2021-12-01)

PD-1/PD-L1 immune checkpoint inhibitors in glioblastoma: clinical studies, challenges and potential
de réir: Tianrui Yang, et al.
Foilsithe / Cruthaithe: (2021-02-01)

PD-L1 expression on malignant cells is no prerequisite for checkpoint therapy
de réir: Jan Willem Kleinovink, et al.
Foilsithe / Cruthaithe: (2017-04-01)

Epigenetic modifications of the immune-checkpoint genes CTLA4 and PDCD1 in non-small cell lung cancer results in increased expression
de réir: Sebastian Marwitz, et al.
Foilsithe / Cruthaithe: (2017-05-01)

Immune Checkpoint Inhibitors in Cancer Therapy
de réir: Yavar Shiravand, et al.
Foilsithe / Cruthaithe: (2022-04-01)

Research Progress on Cardiotoxicity of PD-1/PD-L1 Immune Checkpoint Inhibitors
de réir: YU Lin, et al.
Foilsithe / Cruthaithe: (2021-08-01)

The Role of Immune Checkpoint Inhibitors in Cancer Therapy
de réir: Ahmed M. Basudan
Foilsithe / Cruthaithe: (2022-12-01)

The role of immune checkpoint inhibitors in prostate cancer
de réir: Gabriel Surdacki, et al.
Foilsithe / Cruthaithe: (2019-03-01)

Editorial: The Roles of Checkpoint Inhibitors in Inflammatory Diseases
de réir: Andreas von Knethen, et al.
Foilsithe / Cruthaithe: (2021-10-01)

Activity and Safety of Immune Checkpoint Inhibitors in Neuroendocrine Neoplasms: A Systematic Review and Meta-Analysis
de réir: Alberto Bongiovanni, et al.
Foilsithe / Cruthaithe: (2021-05-01)

Predictive Biomarkers of Immune Checkpoint Inhibitors-Related Toxicities
de réir: Ya Xu, et al.
Foilsithe / Cruthaithe: (2020-10-01)

Structural Characterization of a Macrocyclic Peptide Modulator of the PD-1/PD-L1 Immune Checkpoint Axis
de réir: Edyta Zyla, et al.
Foilsithe / Cruthaithe: (2021-08-01)

The Neonatal Innate Immune Response to Sepsis: Checkpoint Proteins as Novel Mediators of This Response and as Possible Therapeutic/Diagnostic Levers
de réir: Emily Hensler, et al.
Foilsithe / Cruthaithe: (2022-07-01)

Key questions about the checkpoint blockade-are microRNAs an answer?
de réir: Mihnea Dragomir, et al.
Foilsithe / Cruthaithe: (2018-06-01)

Vascular Targeting to Increase the Efficiency of Immune Checkpoint Blockade in Cancer
de réir: Maria Georganaki, et al.
Foilsithe / Cruthaithe: (2018-12-01)

Enhancement of anti-tumor efficacy of immune checkpoint blockade by alpha-TEA
de réir: William L. Redmond, et al.
Foilsithe / Cruthaithe: (2023-02-01)

The epigenetic immunomodulator, HBI-8000, enhances the response and reverses resistance to checkpoint inhibitors
de réir: Reid P. Bissonnette, et al.
Foilsithe / Cruthaithe: (2021-08-01)

Advances in immune checkpoint inhibitors for hepatocellular carcinoma
de réir: Ji Won Han, et al.
Foilsithe / Cruthaithe: (2021-09-01)

Immune Checkpoint Inhibitors: Ctla-4 and Pd-1/Pd-l1 in Immunotherapy
de réir: Kübra KAHVECİ, et al.
Foilsithe / Cruthaithe: (2019-12-01)

Radiation, Immune Checkpoint Blockade and the Abscopal Effect: A Critical Review on Timing, Dose and Fractionation
de réir: Zachary S. Buchwald, et al.
Foilsithe / Cruthaithe: (2018-12-01)

Safety and efficacy of PD-1/PD-L1 immune checkpoint inhibitors in patients with pre-treated advanced stage malignant mesothelioma: a systematic review and meta-analysis
de réir: Amjad Zafar, et al.
Foilsithe / Cruthaithe: (2024-11-01)

The impact of antibiotic use on clinical features and survival outcomes of cancer patients treated with immune checkpoint inhibitors
de réir: Jiaxin Zhou, et al.
Foilsithe / Cruthaithe: (2022-07-01)

Tumor immunotherapies by immune checkpoint inhibitors (ICIs); the pros and cons
de réir: Adel Naimi, et al.
Foilsithe / Cruthaithe: (2022-04-01)

Editorial: Biomarkers of Immune-Checkpoint-Inhibitor Immunotherapies in Hepatocellular Carcinomas
de réir: Zhanjun Guo, et al.
Foilsithe / Cruthaithe: (2022-03-01)

Profiling targetable immune checkpoints in osteosarcoma
de réir: Troy A McEachron, et al.
Foilsithe / Cruthaithe: (2018-12-01)

The Use of Phytochemicals to Improve the Efficacy of Immune Checkpoint Inhibitors: Opportunities and Challenges
de réir: Deniz Can Guven, et al.
Foilsithe / Cruthaithe: (2022-10-01)

Commentary: Chronic PD-1 Checkpoint Blockade Does Not Affect Cognition or Promote Tau Clearance in a Tauopathy Mouse Model
de réir: Kuti Baruch, et al.
Foilsithe / Cruthaithe: (2020-05-01)

NSCLC: from tumorigenesis, immune checkpoint misuse to current and future targeted therapy
de réir: Leona Raskova Kafkova, et al.
Foilsithe / Cruthaithe: (2024-02-01)

Efficacy and safety of immune checkpoint inhibitors in non-small cell lung cancer
de réir: Shuai Wang, et al.
Foilsithe / Cruthaithe: (2018-08-01)

PD/1-PD-Ls Checkpoint: Insight on the Potential Role of NK Cells
de réir: Silvia Pesce, et al.
Foilsithe / Cruthaithe: (2019-06-01)

In Search of Better Peptide-(Derived from PD-L2)-Based Immune Checkpoint Inhibitors
de réir: Boris Klebansky, et al.
Foilsithe / Cruthaithe: (2024-05-01)